(Q37832939)

24 August 2017

1 reference

title

Interferon-α in acute myeloid leukemia: an old drug revisited (English)

1 reference

24 August 2017

1 reference

acute myeloid leukemia

1 reference

S Anguille

1

1 reference

24 August 2017

E Lion

2

1 reference

24 August 2017

Y Willemen

3

1 reference

24 August 2017

V F I Van Tendeloo

4

1 reference

24 August 2017

Z N Berneman

5

1 reference

24 August 2017

E L J M Smits

6

1 reference

24 August 2017

publication date

28 January 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

25

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

739-748

1 reference

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Intracellular innate immune cascades and interferon defenses that control hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

The role of interferon-alpha in the treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Isolation and structure of a human fibroblast interferon gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Construction and identification of bacterial plasmids containing nucleotide sequence for human leukocyte interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Synthesis in E. coli of a polypeptide with human leukocyte interferon activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Continuous delivery of human type I interferons (alpha/beta) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Mechanisms of type-I- and type-II-interferon-mediated signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Close encounters of different kinds: dendritic cells and NK cells take centre stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Interferons, immunity and cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Dendritic cell-based cancer gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Stimulation of naïve and memory T cells by cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Type I interferon as a stimulus for cross-priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Quiescence and functional reprogramming of Epstein-Barr virus (EBV)-specific CD8+ T cells during persistent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

NK cell receptors and their ligands in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Interferon--a major regulator of natural killer cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Helper role of NK cells during the induction of anticancer responses by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Quantification of IFN-gamma produced by human purified NK cells following tumor cell stimulation: comparison of three IFN-gamma assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-gamma secretion by human NK cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Multi-directional cross-regulation of NK cell function during innate immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Graft-versus-leukemia effects of transplantation and donor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Immunotherapy of AML: future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Natural killer cells in haematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Letter: Interferon in acute leukaemia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Alpha interferon in the treatment of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Growth inhibitory effects of interferon on blast cells from patients with acute myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Interferon in chronic myeloid leukaemia: past and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Peginterferon alfa-2a: a review of approved and investigational uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Interferon-alpha enhances artemisinin-induced differentiation of HL-60 leukemia cells via a PKC alpha/ERK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Antiproliferative Properties of Type I and Type II Interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Caspase-8 dependent apoptosis induction in malignant myeloid cells by TLR stimulation in the presence of IFN-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

On the TRAIL of a new therapy for leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G1 phase of the cell cycle and can be increased by interferon treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Antitumor effect of interferon-alpha on U937 human acute leukemia cells in vitro and its molecular mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Interferon induces up-regulation of Spi-1/PU.1 in human leukemia K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Recombinant human interferon sensitizes resistant myeloid leukemic cells to induction of terminal differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Interferons induce normal and aberrant retinoic-acid receptors type alpha in acute promyelocytic leukemia cells: potentiation of the induction of retinoid-dependent differentiation markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

The role of the NKG2D receptor for tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Opposing effect of IFNgamma and IFNalpha on expression of NKG2 receptors: negative regulation of IFNgamma on NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

[The interferons: pharmacology, mechanism of action, tolerance and side effects]

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

IFN- Skews Monocytes into CD56+-Expressing Dendritic Cells with Potent Functional Activities In Vitro and In Vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Acute myeloid leukemia cells fail to activate native human dendritic cells: a potential mechanism of immune evasion

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-alpha 2b

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Effects of interferon and retinoic acid on the growth and differentiation of clonogenic leukemic cells from acute myelogenous leukemia patients treated with recombinant leukocyte-alpha A interferon

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

BCG treatment of residual disease in acute leukemia: studies in a rat model for human acute myelocytic leukemia (BNML)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Value of maintenance therapy with chemotherapy or interferon during remission of acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Treatment of high-risk myelodysplastic syndromes with lymphoblastoid alpha interferon

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

The anti-tumor activities of interferon (IFN)-alpha in chronic myelogenous leukaemia (CML)-derived cell lines depends on the IFN-alpha subtypes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Effects of 5-aza-2'-deoxycytidine and interferon-alpha on differentiation and oncogene expression in HL-60 myeloid leukemic cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Stimulation by interferon of induction of differentiation of human promyelocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Experience with human lymphoblastoid interferon in acute myelogenous leukaemia (AML)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Complete remission in a patient with acute myelogenous leukemia treated with leukocyte alpha-interferon and cimetidine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Low-dose recombinant alfa-2a-interferon: a feasible maintenance therapy in acute myeloid leukaemia in the older patient

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.324

7 January 2021

Identifiers

DOI

10.1038/LEU.2010.324

1 reference

Dimensions Publication ID

24 August 2017

1006860601

0 references

1 reference